What is the first‑line treatment for an uncomplicated urinary tract infection in an otherwise healthy adult woman, and what alternatives are recommended in pregnancy or when nitrofurantoin is contraindicated?

First-Line Treatment for Uncomplicated UTI in Adult Women

Nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days is the preferred first-line treatment for uncomplicated urinary tract infection in otherwise healthy adult women. 1, 2

Primary Recommendation: Nitrofurantoin

Nitrofurantoin has emerged as the optimal first-line agent based on several key advantages:

• Minimal resistance profile: After more than 70 years of clinical use, nitrofurantoin maintains exceptionally low bacterial resistance rates, with no specific resistance threshold established that would preclude its empirical use 2
• Low collateral damage: Unlike fluoroquinolones, nitrofurantoin causes minimal disruption to normal flora and does not contribute significantly to broader antimicrobial resistance 1, 2
• High efficacy: Clinical cure rates range from 88-93%, with microbiological cure rates of 86-92% 2
• Recommended dosing: 100 mg orally twice daily for 5 days 1, 2

Alternative First-Line Options

When nitrofurantoin cannot be used, consider these alternatives in order:

Trimethoprim-Sulfamethoxazole (TMP-SMX)

• Dosing: 160/800 mg (one double-strength tablet) twice daily for 3 days 1
• Critical caveat: Only use if local resistance rates are <20% OR if the infecting strain is known to be susceptible 1
• Resistance concern: Rising resistance rates, particularly outside the United States, have diminished its reliability as empirical therapy 1

Fosfomycin Trometamol

• Dosing: 3 g single oral dose 1
• Advantages: Minimal resistance, low collateral damage, convenient single-dose regimen 1
• Limitation: Appears to have inferior efficacy compared to standard short-course regimens based on FDA data 1

Pivmecillinam

• Dosing: 400 mg twice daily for 3-7 days 1
• Availability: Limited to some European countries; not available in North America 1
• Profile: Minimal resistance and collateral damage, but may have inferior efficacy 1

Agents to Avoid or Reserve

Fluoroquinolones (Ciprofloxacin, Levofloxacin, Ofloxacin)

• Highly efficacious in 3-day regimens but should be reserved for more serious infections 1
• Rationale for avoidance: High propensity for collateral damage and should be preserved for important uses other than acute cystitis 1

Beta-Lactams

• Use only when other recommended agents cannot be used 1
• Options: Amoxicillin-clavulanate, cefdinir, cefaclor, cefpodoxime-proxetil (3-7 day regimens) 1
• Limitations: Generally inferior efficacy and more adverse effects compared to other UTI antimicrobials 1
• Never use: Amoxicillin or ampicillin alone due to poor efficacy and very high worldwide resistance rates 1

Special Considerations for Pregnancy

In pregnant women with uncomplicated UTI, the treatment approach differs:

• Oral antibiotics recommended: Nitrofurans (nitrofurantoin), fosfomycin trometamol, and third-generation cephalosporins are appropriate choices 3
• Cefixime may be particularly rational due to high sensitivity of E. coli, proven efficacy, safety profile, and good compliance in pregnancy 3
• Critical contraindication: Nitrofurantoin is contraindicated in the last three months of pregnancy due to risk of hemolytic anemia in the newborn 4, 5

When Nitrofurantoin is Contraindicated

Nitrofurantoin should not be used in the following situations 4, 5:

• Renal impairment: Creatinine clearance <60 mL/min or clinically significant elevated serum creatinine 4
• Last trimester of pregnancy (months 7-9) 4, 5
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Risk of hemolytic anemia 4
• History of pulmonary reactions to nitrofurantoin 4
• Conditions predisposing to neuropathy: Anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, debilitating disease 4

In these cases, proceed to alternative first-line agents (TMP-SMX if local resistance <20%, fosfomycin, or beta-lactams as outlined above) 1.

Important Safety Warnings for Nitrofurantoin

While nitrofurantoin is first-line therapy, clinicians must be aware of serious but rare adverse effects 4:

• Pulmonary reactions: Acute, subacute, or chronic reactions can occur; chronic reactions (diffuse interstitial pneumonitis or pulmonary fibrosis) develop insidiously, typically with therapy ≥6 months 4
• Hepatotoxicity: Rare but potentially fatal hepatic reactions including hepatitis and hepatic necrosis; monitor for liver injury 4
• Peripheral neuropathy: May become severe or irreversible; enhanced risk with renal impairment, anemia, diabetes, and debilitating conditions 4
• Hemolytic anemia: Occurs in patients with G6PD deficiency (10% of Black individuals, small percentage of Mediterranean/Near-Eastern populations) 4

Clinical Algorithm Summary

1. Confirm uncomplicated UTI in nonpregnant, otherwise healthy adult woman
2. First choice: Nitrofurantoin 100 mg BID × 5 days (unless contraindicated) 1, 2
3. If nitrofurantoin contraindicated:
   • Check local TMP-SMX resistance rates
   • If <20%: TMP-SMX 160/800 mg BID × 3 days 1
   • If ≥20% or patient recently exposed: Fosfomycin 3 g single dose 1
4. If pregnant: Nitrofurantoin (avoid in 3rd trimester), fosfomycin, or cefixime 3
5. Reserve fluoroquinolones for more serious infections 1
6. Use beta-lactams only as last resort when other options unavailable 1